{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001657","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.860784+00:00","generated_at":"2026-06-18T02:49:47.588734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agenus Q4 net loss $74M; botensilimab shows 23% ORR in MSS CRC, 50% in NSCLC","bullets":["Q4 2022 revenue $28.4M, net loss $74.1M ($0.24/sh); FY22 revenue $98M, net loss $230.7M ($0.78/sh).","Cash & short-term investments $193M at Dec 31, 2022, down from $307M a year earlier.","Botensilimab/balstilimab combo: 23% ORR in MSS CRC (70 evaluable), 50% ORR in PD-(L)1 refractory NSCLC (8 evaluable).","Phase 3 confirmatory trial in MSS CRC expected in 2023; randomized Phase 2 ACTIVATE studies ongoing.","Potential future milestones from collaborations up to $2.7B; nine new partner trials launched in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001657","json":"https://secwatch.observer/filing/0001171843-23-001657.json","markdown":"https://secwatch.observer/filing/0001171843-23-001657.md","text":"https://secwatch.observer/filing/0001171843-23-001657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/0001171843-23-001657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/f8k_031423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:49:47.588734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47793e94584a9f92a7f292e938f81a80d0d77554","claim":"AGENUS INC reported financial results for quarter and year ended December 31, 2022.","evidence_excerpt":"On March 14, 2023, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/0001171843-23-001657-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}